Congleton Jon
SEC CIK 1644975 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | CEO, Dir | 603.6K | $105.6K | $17.42M | 20 | 2023-08-11 | 2026-07-13 |
Most active insiders at MLYS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Catalys Pacific Fund, LP | 10% | — | $43.35M |
| 2 | Congleton Jon | CEO, Dir | — | $14.91M |
| 3 | Rodman David Malcom | Chief Medical Off | — | $14.41M |
| 4 | Shah Rajeev M. | Dir | $8.76M | — |
| 5 | Levy Adam Scott | CFO, Sec | — | $6.16M |
| 6 | Warren Eric | Chief Commercial Off | — | $3.30M |
| 7 | Slingsby Brian Taylor | Dir, 10% | — | $3.01M |
| 8 | Gold Alexander M | Dir | — | $1.58M |
| 9 | Karydas Daphne | Dir | — | $925.6K |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-15 20:58 | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $27.24 | -10.7K | 603.6K | -2% | -$291.4K |
| MT | 2026-06-30 18:41 | 2026-06-30 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $26.14 | -75.0K | 614.3K | -11% | -$1.96M |
| T | 2026-04-15 21:45 | 2026-04-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $26.83 | -15.7K | 689.3K | -2% | -$422.0K |
| MT | 2026-04-02 18:54 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $26.27 | -75.0K | 705.1K | -10% | -$1.97M |
| D | 2026-02-20 | 2026-02-19 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | A - Grant | $0.00 | +140.9K | 780.1K | +22% | $0 |
| M | 2026-01-13 | 2026-01-12 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $32.62 | -16.2K | 639.2K | -2% | -$529.7K |
| D | 2025-11-24 | 2025-11-21 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | M - OptEx | $0.54 | +24.1K | 655.4K | +4% | +$13.0K |
| M | 2025-11-13 | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $45.44 | -200.0K | 818.5K | -20% | -$9.09M |
| M | 2025-10-15 | 2025-10-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $42.67 | -15.1K | 832.9K | -2% | -$644.3K |
| 2025-07-15 | 2025-07-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $14.51 | -15.9K | 846.4K | -2% | -$230.5K | |
| 2025-04-15 | 2025-04-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $12.19 | -15.3K | 862.3K | -2% | -$186.7K | |
| 2025-01-15 | 2025-01-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $9.06 | -18.3K | 877.6K | -2% | -$166.1K | |
| 2024-10-15 | 2024-10-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $13.52 | -15.3K | 895.9K | -2% | -$206.5K | |
| 2024-07-12 | 2024-07-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $13.34 | -15.7K | 911.2K | -2% | -$210.1K | |
| M | 2024-06-20 | 2024-06-17+ | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $12.00 | -49.3K | 927.0K | -5% | -$592.0K |
| M | 2024-06-14 | 2024-06-12+ | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | S - Sale | $12.70 | -72.8K | 976.3K | -7% | -$924.4K |
| 2023-11-27 | 2023-11-22 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | P - Purchase | $5.97 | +4,250 | 1.05M | +0.4% | +$25.4K | |
| 2023-09-08 | 2023-09-06 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | P - Purchase | $12.08 | +2,250 | 1.04M | +0.2% | +$27.2K | |
| 2023-08-21 | 2023-08-17 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | P - Purchase | $12.10 | +2,250 | 1.04M | +0.2% | +$27.2K | |
| 2023-08-11 | 2023-08-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO, Dir | P - Purchase | $12.89 | +2,000 | 1.04M | +0.2% | +$25.8K |
Purchase Sale Sale after option exercise All abbreviations